A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

Abstract Background The quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may interfere with the measurements. Methods We developed a two-step immunoass...

Full description

Bibliographic Details
Main Authors: Hedieh Shahpasand-Kroner, Hans-W. Klafki, Chris Bauer, Johannes Schuchhardt, Melanie Hüttenrauch, Martina Stazi, Caroline Bouter, Oliver Wirths, Jonathan Vogelgsang, Jens Wiltfang
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Dementia
Amyloid beta
Blood plasma
Cerebrospinal fluid
Biomarker
Online Access:http://link.springer.com/article/10.1186/s13195-018-0448-x

Internet

http://link.springer.com/article/10.1186/s13195-018-0448-x

Similar Items